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MaBACKGROUND Peripheral vascular intervention (PVI) is an effective treatment option for patients with peripheral
artery disease (PAD). In 2008, Medicare modiﬁed reimbursement rates to encourage more efﬁcient outpatient use of PVI
in the United States.
OBJECTIVES The purpose of this study was to evaluate trends in the use and clinical settings of PVI and the effect
of changes in reimbursement.
METHODS Using a 5% national sample of Medicare fee-for-service beneﬁciaries from 2006 to 2011, we examined
age- and sex-adjusted rates of PVI by year, type of procedure, clinical setting, and physician specialty.
RESULTS A total of 39,339 Medicare beneﬁciaries underwent revascularization for PAD between 2006 and 2011.
The annual rate of PVI increased slightly from 401.4 to 419.6 per 100,000 Medicare beneﬁciaries (p ¼ 0.17), but the
clinical setting shifted. The rate of PVI declined in inpatient settings from 209.7 to 151.6 (p < 0.001), whereas the
rate expanded in outpatient hospitals (184.7 to 228.5; p ¼ 0.01) and ofﬁce-based clinics (6.0 to 37.8; p ¼ 0.008).
The use of atherectomy increased 2-fold in outpatient hospital settings and 50-fold in ofﬁce-based clinics during the
study period. Mean costs of inpatient procedures were similar across all types of PVI, whereas mean costs of
atherectomy procedures in outpatient and ofﬁce-based clinics exceeded those of stenting and angioplasty
procedures.
CONCLUSIONS From 2006 to 2011, overall rates of PVI increased minimally. However, after changes in reimburse-
ment, PVI and atherectomy in outpatient facilities and ofﬁce-based clinics increased dramatically, neutralizing cost
savings to Medicare and highlighting the possible unintended consequences of coverage decisions. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
CPT = current procedural
terminology
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
OPPS = outpatient prospective
payment system
PAD = peripheral artery
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921L ower-extremity peripheral vascular interven-tion (PVI) has supplanted open surgical re-vascularization as the primary mode of
revascularization for patients with peripheral artery
disease (PAD) in the United States. The rate of PVI
increased approximately 3-fold from 1996 to 2006
(1,2). In line with these utilization trends, health care
expenditures for PVI also have risen (1,3,4). By 2005,
inpatient hospital costs accounted for the majority of
overall health care expenditures for patients withSEE PAGE 928
disease
PVI = peripheral vascular
interventionPAD, and mean inpatient costs for patients with PAD
had surpassed inpatient costs for patients with coro-
nary artery disease (3). Faced with these rising costs,
both the National Institutes of Health and the Institute
of Medicine have identiﬁed PAD as a top priority for
future research, with a key focus on health care qual-
ity, costs, and outcomes (5,6).
In 2008, to encourage greater efﬁciency and lower
overall costs, the U.S. Centers for Medicare &
Medicaid Services modiﬁed reimbursement rates for
PVI performed in outpatient hospital settings,
ambulatory surgery centers, and ofﬁce-based clinics
(7). The effect of these changes in reimbursement on
the performance of PVI in outpatient settings, access
to care for patients with PAD, and costs is unknown.
METHODS
DATA SOURCES. We obtained a 5% national sample of
data from the Medicare fee-for-service inpatient,
outpatient, and carrier standard analytic ﬁles as well as
the corresponding denominator ﬁles from 2006 to 2011.
The inpatient ﬁles contain institutional claims for facil-
ity costs covered underMedicare Part A and beneﬁciary,
physician, and hospital identiﬁers; admission and
discharge dates; and diagnosis and procedure codes.
The outpatient ﬁles contain claims from outpatient fa-
cility providers. Noninstitutional provider claims for
services covered under Medicare Part B are included in
the carrier ﬁles. Denominator ﬁles include patient de-
mographic characteristics, birth and death dates, and
information about program eligibility and enrollment.
STUDY POPULATION. From the carrier ﬁles, we
identiﬁed Medicare beneﬁciaries $65 years of age
who had a diagnosis of PAD and a peripheral revas-
cularization procedure on the same claim between
January 1, 2006, and December 31, 2011. We deﬁned
PAD using International Classiﬁcation of Diseases-
Ninth Revision-Clinical Modiﬁcation (ICD-9-CM)
diagnosis code 250.7, 440.0, 440.2x, 440.3x, 440.4,
440.9, 443.9, 444.0, 444.2x, 444.8x, 445.02, 447.1, or
707.1x in any position. We deﬁned peripheralrevascularization procedures using current
procedural terminology (CPT) code 35492,
35493, 35495, 37205 to 8, 35450, 35470, 35473,
35474, 37220 to 37235, 35563, 35565, 35556,
35558, 35566, 35571, 35646, 35661, 35656,
35666, 35351, 35355, 35302, 35371, 35303, or
35304 to 6. We counted all procedure in-
stances, which were deﬁned as 1 per patient
and per day. We limited the study population
to patients enrolled in Medicare fee-for-
service for at least 12 months before the in-
dex revascularization procedure to capture
information about comorbid conditions.
STUDY VARIABLES. We categorized PVI in 3 ways:
1) angioplasty alone, using the CPT code for percuta-
neous transluminal angioplasty and no CPT code for
atherectomy or stent implantation; 2) atherectomy
using the CPT code for atherectomy with or without a
code for angioplasty or stent; and 3) stent implanta-
tion using the CPT code for stent implantation with
or without a code for angioplasty and without a code
for atherectomy. We categorized surgical revascular-
ization using CPT codes as either lower-extremity
bypass or endarterectomy. We categorized hybrid
revascularization using CPT codes for PVI and surgi-
cal revascularization on the same claim.
Clinical setting, as deﬁned by the location of care
that was received on the physician claim, could
include inpatient facility, outpatient facility, ofﬁce-
based clinic, or ambulatory surgery center. On the
basis of physician specialty codes, we categorized
provider specialty as surgery (vascular, cardiovascu-
lar, and general), cardiology, radiology, and other.
PATIENT CHARACTERISTICS. Patient demographic
characteristics included age, sex, race, and U.S. geo-
graphic region. We used previously validated methods
to identify comorbid conditions with ICD-9-CM diag-
nosis codes on the claims billed to Medicare for up to
365 days before the date of the index procedure (8,9).
Speciﬁcally, we searched all inpatient, outpatient, and
carrier claims for the 365 days preceding January 1 of
each study year for evidence of chronic obstructive
pulmonary disease (ICD-9-CM codes 416.8, 416.9, 490 to
505, 506.4, 508.1, and 508.8), heart failure (428.x,
398.91, 402.x1, 404.x1, 404.x3, and 425.4 to 425.9), cor-
onary artery disease (410.x to 414.x, 429.2, and V45.81),
dementia (290.x, 294.1, and 331.2), diabetes mellitus
(250), hypertension (401 to 405 and437.2), cancer (140 to
172, 174 to 195, 200 to 208, and 238.6), renal disease
(403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13,
404.92, 404.93, 582.x, 583.0 to 583.7, 585.x, 586.x,
588.0, V42.0, V45.1, and V56.x), and stroke or transient
ischemic attack (435, 436, 4371, 4379, 438, 3401, 43411,
43491, 43301, 43311, 43321, 43331, 43381, and 43391).
FIGURE 1 Flow Diagram of the Assignment of Medicare Beneﬁciaries to
Peripheral Vascular Intervention Categories
All Patients
Undergoing Revascularization
N = 39,339
Surgical
Revascularization
N = 7,325 (18.6%)
Hybrid
Revascularization
N = 766 (2.0%)
Peripheral Endovascular 
Intervention (PVI)
N = 31,248 (79.4%)
Atherectomy
N = 6,991
Stent
N = 15,710
Angioplasty
N = 8,547
Flow diagram demonstrating the assignment of Medicare beneﬁciaries to categories
(atherectomy, stenting, or angioplasty). Patients who underwent surgical revascularization
and hybrid revascularization during the study period were excluded. Overall, 31,248
Medicare patients underwent peripheral endovascular intervention and were included
in the current analysis.
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922COST ANALYSIS. We deﬁned Medicare expenditures
as the amount paid by both the Medicare program
and Medicare beneﬁciaries for care received on the
date of the revascularization procedure. Expenditures
included payments on inpatient, outpatient, and
carrier claims. Given the extreme variability in costs
for inpatient procedures, we restricted inpatient cost
data to patients undergoing elective hospital admis-
sion and having an inpatient stay of #3 days.
STATISTICAL ANALYSIS. We described patient and
clinical characteristics of the study population as fre-
quencies with percentages for categorical variables
and medians with interquartile ranges for continuous
variables. To test for differences between groups,
we used chi-square tests for categorical variables
and Kruskal-Wallis tests for continuous variables. We
calculated the annual rates of lower-extremity revas-
cularization procedures and the annual rates of PVI on
the basis of 3 factors: clinical setting, type of PVI, and
physician specialty. We adjusted all rates for age and
sex to the Medicare fee-for-service population and
report themas rates per 100,000beneﬁciaries.Weused
linear regression to test for linear temporal trends. The
institutional review board of the Duke University
Health System reviewed and approved this study.We used SAS statistical software version 9.2 (SAS
Institute Inc., Cary, North Carolina) for all analyses.
RESULTS
In a 5% sample of Medicare fee-for-service beneﬁ-
ciaries, we identiﬁed 39,339 patients who underwent
lower-extremity revascularization procedures bet-
ween 2006 and 2011. Figure 1 shows the ﬂow diagram of
patients included in the study. Of the 39,339
total patients, 31,248 (79.4%) underwent PVI, 7,325
(18.6%) underwent surgical revascularization pro-
cedures, and 766 (2.0%) underwent hybrid revascular-
izationprocedures. Of the patientswhounderwent PVI,
27.3% had angioplasty alone (with no atherectomy or
stent), 22.4% had atherectomy (with or without angio-
plasty or stent), and 50.3%had stent implantation (with
or without angioplasty, and with no atherectomy).
Table 1 shows the characteristics of the study
population. Patients who underwent PVI with athe-
rectomy or angioplasty alone were older, more likely
to be men, more likely to be black, and more likely to
have renal failure, diabetes mellitus, heart failure,
and stroke, compared with patients who underwent
PVI with stenting. Patients who underwent PVI with
atherectomy also were more likely to have ischemic
heart disease, be treated by a cardiologist, and reside
in the Midwest or South, compared with patients who
underwent PVI with angioplasty alone or stenting.
Table 2 shows age- and sex-adjusted procedure
rates per 100,000 Medicare beneﬁciaries. The overall
rate of PVI increased slightly from 401.4 in 2006 to
419.6 in 2011 (p ¼ 0.17). This increase in the use of PVI
was offset by a reduction in the rate of surgical
revascularization procedures from 115.5 in 2006 to
77.8 in 2011 (p < 0.001). The rate of hybrid revascu-
larization procedures remained stable. PVI with an-
gioplasty alone (97.7 in 2006 to 109.4 in 2011) and
atherectomy (96.4 in 2006 to 125.9 in 2011) increased
during the study period, and the use of stents
decreased modestly (207.4 in 2006 to 184.3 in 2011).
We observed a marked reduction in the rate of PVI
performed in inpatient hospital settings (209.7 in 2006
to 151.6 in 2011) (Central Illustration, Table 3). There
was a concomitant increase in the rate of PVI per-
formed in outpatient hospital settings (184.7 in 2006
to 228.5 in 2011) and ofﬁce-based clinics (6.0 in 2006 to
37.8 in 2011). The rate of atherectomy in outpatient
hospital settings and ofﬁce-based clinics underwent
the largest effective change after the 2008 Medicare
payment change (38.6 in 2006 vs. 83.7 in 2011).
The majority of PVIs were performed by surgeons
and cardiologists. By the end of the study period, the
rate of PVI performed by surgeons (140.1 in 2006 to
TABLE 1 Characteristics of Patients Undergoing Peripheral Vascular Intervention, 2006 to 2011
Overall
(N ¼ 31,248)
Atherectomy
(n ¼ 6,991)
Stent
(n ¼ 15,710)
Angioplasty
(n ¼ 8,547) p Value
Age, yrs 76.0 (71.0–82.0) 77.0 (71.0–82.0) 76.0 (71.0–81.0) 77.0 (72.0–83.0) <0.001
Male 14,191 (45.4) 3,282 (46.9) 6,987 (44.5) 3,922 (45.9) 0.002
Race <0.001
Black 3,817 (12.2) 994 (14.2) 1,626 (10.4) 1,197 (14.0)
White 26,112 (83.6) 5,633 (80.6) 13,528 (86.1) 6,951 (81.3)
Other 1,319 (4.2) 364 (5.2) 556 (3.5) 399 (4.7)
Medical history
Acute MI 6,174 (19.8) 1,390 (19.9) 3,051 (19.4) 1,733 (20.3) 0.27
Cancer 4,676 (15.0) 1,013 (14.5) 2,335 (14.9) 1,328 (15.5) 0.17
COPD 13,406 (42.9) 2,880 (41.2) 7,012 (44.6) 3,514 (41.1) <0.001
Renal failure 8,859 (28.4) 2,037 (29.1) 4,129 (26.3) 2,693 (31.5) <0.001
Diabetes mellitus 16,771 (53.7) 4,078 (58.3) 7,697 (49.0) 4,996 (58.5) <0.001
Dementia 1,696 (5.4) 385 (5.5) 765 (4.9) 546 (6.4) <0.001
Heart failure 11,745 (37.6) 2,740 (39.2) 5,458 (34.7) 3,547 (41.5) <0.001
Hypertension 29,383 (94.0) 6,643 (95.0) 14,669 (93.4) 8,071 (94.4) <0.001
Ischemic heart disease 22,768 (72.9) 5,270 (75.4) 11,300 (71.9) 6,198 (72.5) <0.001
Stroke/TIA 7,019 (22.5) 1,537 (22.0) 3,428 (21.8) 2,054 (24.0) <0.001
Geographic region <0.001
Midwest 8,596 (27.5) 2,042 (29.2) 4,182 (26.6) 2,372 (27.8)
Northeast 4,585 (14.7) 705 (10.1) 2,542 (16.2) 1,338 (15.7)
South 14,059 (45.0) 3,351 (47.9) 6,988 (44.5) 3,720 (43.5)
West 4,008 (12.8) 893 (12.8) 1,998 (12.7) 1,117 (13.1)
Clinical setting <0.001
Inpatient 13,767 (44.1) 3,229 (46.2) 6,689 (42.6) 3,849 (45.0)
Ofﬁce 1,304 (4.2) 292 (4.2) 650 (4.1) 362 (4.2)
Outpatient 16,074 (51.4) 3,459 (49.5) 8,320 (53.0) 4,295 (50.3)
Other 103 (0.3) 11 (0.2) 51 (0.3) 41 (0.5)
Physician specialty <0.001
Cardiology 12,310 (39.4) 3,658 (52.3) 6,108 (38.9) 2,544 (29.8)
Radiology 4,943 (15.8) 539 (7.7) 2,643 (16.8) 1,761 (20.6)
Surgery 12,046 (38.5) 2,352 (33.6) 555 (37.9) 3,739 (43.7)
Other 1,949 (6.2) 442 (6.3) 1,004 (6.4) 503 (5.9)
Year of procedure <0.001
2006 4,986 (16.0) 1,199 (17.2) 2,580 (16.4) 1,207 (14.1)
2007 5,034 (16.1) 1,104 (15.8) 2,578 (16.4) 1,352 (15.8)
2008 5,053 (16.2) 903 (12.9) 2,732 (17.4) 1,418 (16.6)
2009 5,293 (16.9) 1,000 (14.3) 2,755 (17.5) 1,538 (18.0)
2010 5,334 (17.1) 1,124 (16.1) 2,627 (16.7) 1,583 (18.5)
2011 5,548 (17.8) 1,661 (23.8) 2,438 (15.5) 1,449 (17.0)
Values are median (interquartile range) or n (%).
COPD ¼ chronic obstructive pulmonary disease; MI ¼ myocardial infarction; TIA ¼ transient ischemic attack.
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923177.5 in 2011) surpassed the rate of PVI performed by
cardiologists (154.9 in 2006 to 166.9 in 2011). The
proportion of PVIs performed by radiologists con-
tinued to decline from 81.0 in 2006 to 50.8 in 2011
(Central Illustration).
Table 4 shows mean payments for PVI in inpatient
hospital settings, outpatient hospital settings, and
ofﬁce-based clinics. Mean payments for all inpatient
PVIs were higher than payments for PVIs in outpatient
settings and ofﬁce-based clinics. Mean payments for
angioplasty and stenting procedures in outpatientsettings and ofﬁce-based clinics increased steadily
between 2006 and 2011, whereas there was a 100%
increase in costs for outpatient atherectomies between
2006 and 2008 (at the time of the change in Medicare
payments) and an additional 50% increase between
2008 and 2011 (after the change). Few ofﬁce-based
atherectomies were performed between 2006 and
2010. However, in 2011, the mean costs of ofﬁce-based
atherectomies ($13,478) mirrored inpatient pro-
cedure costs and exceeded the mean costs of out-
patient atherectomies ($8,680), ofﬁce-based stenting
TABLE 2 Age- and Sex-Adjusted Rates of Peripheral Vascular Interventions, Surgical Revascularization Procedures, and
Hybrid Procedures per 100,000 Medicare Beneﬁciaries by Year
2006 2007 2008 2009 2010 2011 p Value
Peripheral vascular intervention 4,986 (401.4) 5,034 (367.6) 5,053 (379.0) 5,293 (400.7) 5,334 (406.7) 5,548 (419.6) 0.17
Angioplasty 1,207 (97.7) 1,352 (98.6) 1,418 (106.4) 1,538 (116.4) 1,583 (120.6) 1,449 (109.4) 0.07
Atherectomy 1,199 (96.4) 1,104 (80.7) 903 (67.7) 1,000 (75.7) 1,124 (85.8) 1,661 (125.9) 0.38
Stent 2,580 (207.4) 2,578 (188.3) 2,732 (205.0) 2,755 (208.6) 2,627 (200.4) 2,438 (184.3) 0.44
Surgical revascularization 1,452 (115.6) 1,330 (97.6) 1,184 (89.1) 1,157 (87.7) 1,175 (89.8) 1,027 (77.8) 0.02
Bypass 1,247 (99.1) 1,073 (78.7) 922 (69.4) 910 (69.0) 902 (69.0) 796 (60.3) 0.02
Endarterectomy 205 (16.4) 257 (18.9) 262 (19.7) 247 (18.7) 273 (20.9) 231 (17.4) 0.52
Hybrid procedure 110 (8.8) 117 (8.6) 135 (10.2) 130 (9.9) 129 (9.8) 145 (11.0) 0.03
Values are n (rate per 100,000 beneﬁciaries).
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924procedures ($6,379), and ofﬁce-based angioplasty
procedures ($4,800). As shown in Online Table 1, mean
costs for ofﬁce-based atherectomy procedures were
signiﬁcantly different for atherectomy alone ($11,893)
versus atherectomy plus stenting ($16,445).
DISCUSSION
Studies in the late 1990s and early 2000s reported a
sharp rise in both the numbers and the overall costs of
PVI, with a majority of the costs attributable to pro-
cedures performed in inpatient hospital settings
(1–3,10). Accordingly, U.S. Centers for Medicare &
Medicaid Services implemented changes in the
outpatient prospective payment system (OPPS) in
2008 that led to the establishment of “ambulatory
payment classiﬁcations” and bundling of payments
for PVIs in outpatient facilities and ofﬁce-based
clinics (11). Our study of temporal trends and the
rates and settings of PVI after changes in Medicare
reimbursement had 3 main ﬁndings. First, the pro-
portion of PVIs, and particularly atherectomy pro-
cedures, performed in outpatient hospital settings
and ofﬁce-based clinics increased signiﬁcantly after
the change to the OPPS. Second, mean Medicare ex-
penditures for PVI were signiﬁcantly higher for
atherectomy procedures than for angioplasty and
stenting procedures. Finally, the rate of growth in PVI
stabilized between 2006 and 2011, but the rate of
growth of atherectomy outpaced other modalities
(i.e., angioplasty alone, stent implantation). In total,
with the changes in reimbursement in 2008, overall
Medicare expenditures for PVI likely decreased as a
result of the shift in clinical settings for PVI; however,
the expected cost savings were offset by greater use
of more expensive atherectomies.
With changes in Medicare reimbursement, it is
unsurprising that the use of PVI increased in outpa-
tient hospital settings and ofﬁce-based clinicsbecause the main impetus for the changes was to
provide incentives for outpatient use of these pro-
cedures, encourage greater efﬁciency, and ultimately,
lower the overall costs of PVI to the Medicare program
(7). In fact, we observed a 25% relative decline in PVI
in inpatient facilities and a similar relative increase in
PVI in outpatient facilities. A striking ﬁnding was the
5-fold increase in PVI in ofﬁce-based clinics, espe-
cially as recent commentaries from practice manage-
ment experts and professional societies have
documented the increasing ownership of ofﬁce-based
clinics by physicians rather than hospitals or health
care systems (11). We were unable to determine the
ownership of ofﬁce-based clinics in this study. A
major reason for physicians to perform procedures in
ofﬁce-based clinics is to capture the entire bundled
fee, rather than just the professional fees for inpa-
tient (and outpatient) facility services. To our
knowledge, no prior study has focused on the rela-
tionship between changes in reimbursement and
trends in the clinical setting of PVI.
In addition to evaluating the shift of PVI to
outpatient settings and ofﬁce-based clinics, we also
measured overall Medicare costs for PVI, including
costs of facility services, nonfacility services (ofﬁce-
based clinics), and ambulatory payment classiﬁca-
tions (the method of payment for facility outpatient
services during the study period). Although inpatient
facility costs likely overestimate costs for inpatient
PVI, we restricted estimates of inpatient expenditures
to procedures that were designated as elective and
those associated with a hospital stay of <3 days.
Throughout the study period, expenditures for an-
gioplasty with or without stenting in inpatient set-
tings were signiﬁcantly higher than expenditures in
outpatient settings and ofﬁce-based clinics. After
changes in the OPPS, Medicare payments for outpa-
tient and ofﬁce-based clinic atherectomies were the
highest reimbursed procedures and mirrored
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(Top) Graph depicting the age- and sex-adjusted rates of peripheral vascular intervention
(PVI) according to clinical setting (inpatient, outpatient, and ofﬁce-based clinics). The rate
of inpatient PVI declined by approximately 25%, whereas the rate of outpatient PVI
increased by approximately 25%. The rate of PVI occurring in ofﬁce-based clinics
increased from 6 procedures per 100,000 Medicare beneﬁciaries in 2006 to 37.8 pro-
cedures per 100,000 Medicare beneﬁciaries in 2011. (Bottom) Graph depicting the age-
and sex-adjusted rates of PVI according to physician specialty (vascular or general surgery,
cardiology, and radiology). By the end of the study period, the rate of PVI performed by
surgeons (140.1 in 2006 to 177.5 in 2011) surpassed the rate of PVI performed by cardi-
ologists (154.9 in 2006 to 166.9 in 2011). The proportion of PVIs performed by radiolo-
gists continued to decline from 81.0 in 2006 to 50.8 in 2011.
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925payments for inpatient atherectomies. Although total
Medicare expenditures for PVI almost certainly
declined as a result of declining rates of inpatient
PVI during the study period, the increase in all athe-
rectomies likely reduced the effect of these cost sav-
ings to Medicare, because of the signiﬁcantly higher
reimbursement for atherectomy in all settings.
Atherectomy use increased from 7 procedures per
100,000 beneﬁciaries in 2003 (1) to 125 procedures in
2011. A recent systematic review from the Cochrane
Peripheral Vascular Diseases Group details the 4
randomized controlled trials comparing atherectomy
to other established treatments (12). These 4 studies
randomly assigned a total of 220 subjects (118 to
atherectomy, 102 to balloon angioplasty) and found
no statistically signiﬁcant difference in initial proce-
dural success, vessel patency at 6 months, and vessel
patency at 12 months (13–16). No comparative-
effectiveness studies with atherectomy have been
performed, and for regulatory considerations, athe-
rectomy devices operate through a pre-market noti-
ﬁcation or 510(k) approval mechanism.
With randomized data lacking to support its use,
the signiﬁcant rise in atherectomy use during the
study period in outpatient facilities and ofﬁce-based
clinics is likely related to higher reimbursement for
atherectomy procedures. Another potential explana-
tion is the introduction of better atherectomy tech-
nology for use during PVI; however, we were not able
to explore this possibility with the current dataset.
More than one-half of all ofﬁce-based clinic pro-
cedures in 2011 were atherectomies, which is more
than double the rate occurring in either inpatient or
outpatient hospital settings. We observed signiﬁcant
differences in mean payments for services provided
in outpatient facilities and ofﬁce-based clinics. Pay-
ments for outpatient and ofﬁce-based atherectomies
were higher than payments for angioplasty, likely
contributing to the continued rise in the use of these
devices. In sum, reimbursement rates likely contrib-
uted to the more frequent use of atherectomy during
the study period, and this increased use likely
neutralized some of the cost savings to Medicare after
changes to the OPPS, despite a lack of efﬁcacy data
supporting atherectomy use.
The treatment landscape for patients with symp-
tomatic PAD has changed with the rapid expansion of
PVI, as shown in multiple studies from national
datasets in the late 1990s and early 2000s (1–3,17).
Some of the studies were limited to the National
Inpatient Sample, which does not allow for evalua-
tion of the full spectrum of revascularization pro-
cedures, including procedures in outpatient facilities
and ofﬁce-based clinics (2,10,17). These studies alsowere limited by the use of ICD-9-CM procedure codes,
rather than CPT codes, which are not speciﬁc enough
to identify speciﬁc treatment modalities (angioplasty,
atherectomy, or stenting). Our study represents a
contemporary report on the state of endovascular
TABLE 3 Age- and Sex-Adjusted Rates of Peripheral Vascular Interventions per 100,000 Medicare Beneﬁciaries
by Clinical Setting and Year
Setting 2006 2007 2008 2009 2010 2011 p Value
Total procedures
Inpatient 2,593 (209.7) 2,572 (187.8) 2,374 (178.0) 2,186 (165.3) 2,034 (154.8) 2,008 (151.6) <0.001
Outpatient 2,306 (184.7) 2,387 (174.3) 2,484 (186.4) 2,844 (215.4) 3,033 (231.6) 3,020 (228.5) 0.01
Ofﬁce 75 (6.0) 56 (4.1) 175 (13.2) 242 (18.4) 258 (19.7) 498 (37.8) 0.008
Angioplasty
Inpatient 608 (49.4) 705 (51.5) 684 (51.3) 634 (48.0) 632 (48.0) 586 (44.2) 0.06
Outpatient 570 (46.0) 616 (44.9) 670 (50.3) 815 (61.7) 847 (64.7) 777 (58.7) 0.03
Ofﬁce 24 (1.9) 24 (1.8) 52 (3.9) 82 (6.2) 102 (7.8) 78 (5.9) 0.02
Atherectomy
Inpatient 718 (57.7) 640 (46.8) 453 (34.0) 446 (33.7) 422 (32.2) 550 (41.6) 0.14
Outpatient 476 (38.3) 464 (33.8) 446 (33.4) 548 (41.5) 692 (52.8) 833 (63.2) 0.03
Ofﬁce —* —* —* —* —* 270 (20.5) 0.23
Stent
Inpatient 1,267 (102.6) 1,227 (89.5) 1,237 (92.7) 1,106 (83.6) 980 (74.6) 872 (65.8) 0.002
Outpatient 1,260 (100.5) 1,307 (95.6) 1,368 (102.7) 1,481 (112.2) 1,494 (114.1) 1,410 (106.6) 0.10
Ofﬁce 47 (3.8) 32 (2.3) 119 (9.0) 156 (11.9) 146 (11.2) 150 (11.4) 0.03
Values are n (rate per 100,000 beneﬁciaries). *The Centers for Medicare & Medicaid Services cell size suppression policy stipulates that no cell containing data for fewer than
11 observations may be displayed.
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926care for patients with lower-extremity PAD in all
clinical settings and distinguishes between treatment
modalities.
STUDY LIMITATIONS. First, symptoms and severity
of PAD are not accurately captured in Medicare claims
data. Second, the analysis included only patients who
were age 65 years and older and enrolled in fee-for-
service Medicare; generalizability to other patients
is unclear. Third, Medicare claims data do not contain
information on disease complexity, anatomy, and
calciﬁcation, all factors that may inﬂuence the use
of angioplasty, atherectomy, and stenting. Finally,
estimation of Medicare expenditures is not speciﬁcTABLE 4 Total Costs of Peripheral Vascular Intervention by Procedu
Setting 2006 2007 2008
Atherectomy
Inpatient 11,342  4,295 11,688  4,094 12,583  4
Outpatient 2,763  1,920 3,226  2,291 5,720  3
Ofﬁce —† —† —†
Stent
Inpatient 11,589  4,179 11,960  4,796 11,994  3
Outpatient 4,367  2,541 4,562  2,756 6,012  3
Ofﬁce 1,678  1,724 1,432  1,502 5,402  2
Angioplasty
Inpatient 11,044  3,736 11,554  3,904 11,796  3
Outpatient 2,374  1,441 2,361  1,568 2,734  1
Ofﬁce 3,789  1,520 3,511  1,478 3,781  1
Values are in U.S. dollars and are presented as mean  SD. *Costs include professional an
Medicaid Services cell size suppression policy stipulates that no cell containing data forto PVI in inpatient settings. Therefore, we may have
overestimated expenditures for inpatient PVI com-
pared with outpatient and ofﬁce-based PVI despite
our attempt to limit inpatient PVI to elective and
short hospitalizations.
CONCLUSIONS
The rate of growth in PVI has stabilized. A decline
in revascularization in inpatient settings was offset
by a rise in procedures in outpatient hospital
settings and ofﬁce-based clinics. The rate of athe-
rectomy use in lower-extremity interventions con-
tinues to increase, despite a relative dearth inre, Setting, and Year*
2009 2010 2011
,568 13,122  5,511 12,945  6,896 11,446  6,383
,732 6,790  3,909 7,204  4,142 8,680  4,970
—† —† 13,478  4,768
,825 12,550  4,634 12,901  6,351 12,466  7,077
,329 6,858  3,356 7,341  3,693 5,982  3,639
,643 5,543  2,292 5,542  1,914 6,379  2,986
,739 11,820  4,674 11,623  3,590 13,197  4,711
,670 3,164  1,738 3,437  1,902 3,742  2,014
,566 3,472  1,400 3,546  1,551 4,800  2,028
d facility costs and patient deductibles and coinsurance. †The Centers for Medicare &
fewer than 11 observations may be displayed.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: Physicians,
health care administrators, policy makers, and consumers should
be aware that changes in reimbursement policy intended to
improve access to and efﬁciency of care and reduce costs may
have unintended consequences when they promote shifts in the
proportion of interventional procedures for a given clinical
indication.
TRANSLATIONAL OUTLOOK: Additional research is needed
to examine the clinical outcomes of peripheral arterial interven-
tions associated with changes in reimbursement policies and
proportionate use of atherectomy compared with angioplasty
and stenting in relation to patient-, provider-, and setting-
speciﬁc factors.
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927comparative-effectiveness and safety data to sup-
port its use. The goal of the modiﬁcations to the
OPPS was to reduce costs, improve access to care,
and encourage efﬁcient delivery of care. The
current study sheds light on possible unintended
consequences of these payment decisions and
highlights the need for further clinical studies to
demonstrate the effectiveness and value of device
technologies such as atherectomy.
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